We understand the science of value
As trusted partners, our areas of expertise stretch from demonstrating value through evidence-based health economics to helping clients maximize access in new and emerging therapies. With more than two decades of experience supporting products in multiple therapeutic classes, we help brands anticipate and address the demands of value-based care at every stage of the product life cycle.
You have goals. We have expertise to reach them.
Health Economics and Outcomes Research
From complementing your in-house HEOR experts to conducting research and analysis on your behalf, our global HEOR capabilities are tailored to fit your needs.
Market Access and Reimbursement
Gain insights into the payer mindset and translate evidence into powerful messages and strategic plans that distinguish your brand for successful product launch.
Overcome barriers to patient access and optimize relationships between provider, patient hub, and payer with the pioneers in field reimbursement.
Generate robust real-world evidence across a wide spectrum of criteria with our data-driven solutions that prove product value and maximize patient access.
Global Market Intelligence
Whether you need insights from payers, providers, or patients, our experts create customized engagements that tap into the minds of critical stakeholders.
Helping your therapeutic innovations thrive
We're built to help you navigate the increasingly complex decisions related to oncology product development and commercialization.
Cell and Gene Therapy
Transform patient outcomes in this clinically promising yet commercially challenging new frontier of medicine.
From supporting the first U.S. biosimilar to conducting landmark coding and reimbursement research, gain key guidance in this emerging landscape.
Stay on top of an evolving landscape
Proactively position for value-based care
Understanding how payers evaluate products is key as the value-based landscape evolves. Gain insights into a wide array of methodologies and frameworks to present the most salient evidence required to survive the scrutiny.
Translate new HCEI guidance for maximum opportunity
The 21st Century Cures Act has given greater clarity to FDAMA 114, allowing new possibilities for pre-approval and proactive payer communication. Develop a strategy and suite of tools that embraces the new standards to favorably position your product in the minds of key stakeholders.